Authors

Latest:

Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRC

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

Moh’d Khushman, MD

Latest:

Dr. Khushman on Best Practices in the Management of GI Cancers

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Charlotte Schubert, PhD

Lydia Mills

Latest:

Palliative Care Can Address Gaps in Oncology Landscape

Palliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.

Victoria Johnson

Latest:

FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemia

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.

Kevin Hakimi

Latest:

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

Margot O’Neill, PA-C, MHS

Latest:

Unmet Needs and Future Perspectives in Colorectal Cancer

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Benjamin V. Stone, MD

Latest:

Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate Cancer

Benjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.

Maria I. Carlo, MD

Latest:

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Sandip P. Patel, MD, University of California San Diego

Latest:

Perioperative Approaches to NSCLC

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Triparna Sen, PhD

Latest:

Insights from ARTEMIS-001

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

Aaron LeBeau, PhD

Latest:

Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate Cancer

Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.

Noah Kalman, MD, MBA

Latest:

Tumor-Killing Technology in Head and Neck Cancer

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Jorge Nieva, MD

Latest:

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Adrián Mosquera Orgueira, MD, PhD,

Adrián Mosquera Orgueira, MD, PhD, is a specialist in Hematology and Hemotherapy and lead researcher of the Computational and Genomic Hematology Group at the Health Research Institute of Santiago de Compostela.

Latest:

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

Thomas Bachelot, MD, PhD

Latest:

Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases

Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.

Radhika Bansal, MBBS

Latest:

Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

Ruth O'Regan, MD, University of Rochester Medical Center

Latest:

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Ben Levy, MD, The Johns Hopkins University School of Medicine

Latest:

Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

Jameel Muzaffar, MD

Latest:

Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCC

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.